APX-343A alone or with pembrolizumab for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, Phase 1 dose-escalation trial with two parts: Part A tests APX-343A monotherapy and Part B tests APX-343A combined with pembrolizumab. The main goals are to define safety, tolerability, and pharmacokinetics, and to look for preliminary signs of anti-tumor activity using RECIST v1.1 measures. Eligible participants must be adults with histologically confirmed advanced solid tumors, ECOG 0–1, measurable disease, and provide tumor tissue or a fresh biopsy. Dosing cohorts will be escalated per protocol to identify recommended doses for further study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female subjects aged ≥19 years, inclusive, at the time of informed consent.
2. Willing and able to give informed consent and to comply with the requirements of the study.
3. Histologically or cytologically confirmed advanced solid tumor.
4. Life expectancy of at least 3 months in the judgment of the investigator.
5. ECOG performance status of 0 to 1 during the screening period.
6. Measurable disease per RECIST v1.1 as assessed by the site investigator/radiology.
7. Archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated has been provided.
8. Subjects who have AEs due to previous anticancer therapies must have recovered to ≤ Grade 1 or baseline.
9. Adequate organ function as defined in the following table.
10. Subjects who are hepatitis B surface antigen positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to the first dose of study drug.
11. Subjects with history of HCV infection are eligible if HCV viral load is undetectable at screening.
12. Male subjects must agree to use an adequate method of contraception.
13. Female subjects of childbearing potential must agree to use highly effective contraceptive methods, and to abstain from breastfeeding.

Exclusion Criteria:

1. Received any prior immunotherapy.
2. Received prior systemic anticancer therapy including investigational agents.
3. Received prior radiotherapy.
4. Received a live or live-attenuated vaccine .
5. Has received an investigational agent.
6. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
7. Known additional malignancy.
8. Known active CNS metastases and/or carcinomatous meningitis.
9. Active autoimmune disease.
10. History of (noninfectious) pneumonitis/interstitial lung disease.
11. Active, uncontrolled infection requiring systemic therapy.
12. Unable to swallow study drug or disease that interfere with proper absorption of study drug.
13. Significant cardiovascular disease.
14. Cerebrovascular accident.
15. History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the subject's ability to cooperate with the requirements of the study.
16. History of severe hypersensitivity to pembrolizumab and/or any of its excipients.
17. History of hypersensitivity to APX-343A and/or any of its excipients.
18. History of allogeneic tissue/solid organ transplant.
19. History of HIV infection or HIV positive at screening.
20. Subjects who have not adequately recovered from major surgery or have ongoing surgical complications.

Where it's running

• Seoul National University Bundang Hospital
  Seongnam, South Korea Recruiting
• Gangnam Severance Hospital, Yonsei University Health System
  Seoul, South Korea Recruiting
• Severance Hospital, Yonsei University Health System
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Clinical Center, Clinical Center
• Email: cd@aptabio.com
• Phone: +82-31-365-3693

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin in untreated locally advanced or metastatic urothelial cancer

  This trial tests if adding ivonescimab to enfortumab vedotin works better than pembrolizumab plus enfortumab vedotin for people with untreated locally advanced or metastatic urothelial cancer.

  Recruiting at 2 sites Phase 2/3 Summit Therapeutics · Phoenix, Arizona and 6 other locations · NCT07815665

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.